Skip Ribbon Commands
Skip to main content

Find A Doctor

Associate Professor Edmund Chiong

Photo of Associate Professor Edmund Chiong
Credential:
MBBS (Singapore), Ph.D, FRCSEd, FRCSI, FAMS (Urology)
Designation:
Head & Senior Consultant, Department of Urology, National University Hospital
Senior Consultant, Division of Surgical Oncology, National University Cancer Institute, Singapore
Associate Professor, Department of Surgery, Yong Loo Lin School of Medicine, NUS
Associate Chairman, Medical Board (Research), NUH
Director of Urologic Oncology, Department of Urology, NUH
Director of Research, Department of Urology, NUH

Specialty:
Cancer, Surgery
Sub Specialty:
Surgical Oncology (Urology), Urology
Medical and Surgical Conditions:
Adrenal Cancer, Benign Prostate Hyperplasia, Bladder Cancer, Erectile Dysfunction, Kidney Cancer (Renal Cancer), Kidney Stones, Penis Cancer (Penile Cancer), Prostate Cancer, Testicular Cancer (Testis Cancer), Ureteric Cancer (Ureteral Cancer), Urethral Cancer, Urinary Incontinence
Special Interest:
Uro-oncology (Prostate cancer, Kidney cancer, Bladder cancer, Testicular cancer and Penile cancer)
Prostate cancer High-Dose Rate Brachytherapy
Da Vinci Robotic surgery
General Urology
Institution:
National University Hospital
National University Cancer Institute, Singapore
National University Health System
A/Prof Edmund Chiong graduated with the degrees of Bachelor of Medicine and Surgery from the National University of Singapore (NUS) in 1995. He obtained postgraduate qualifications (Fellow of the Royal College of Surgeons of Edinburgh and Fellow of the Royal College of Surgeons In Ireland) in Surgery (in 2000) and completed of his Urology specialist training in Singapore. A/Prof Chiong subsequently completed a 2-year clinical fellowship program in Urologic Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.  He is also certified by the Society of Urologic Oncology, USA.

A/Prof Chiong’s subspecialty interests include managing and performing surgery for prostate cancers, bladder cancers, kidney cancers, testes cancers, penile cancers, and performing DaVinci robotic surgery. A/Prof Chiong also manages general urologic diseases and is a kidney transplant surgeon with the Ministry of Health’s renal transplantation team. Apart from clinical practice, A/Prof Chiong is also actively involved in both clinical and laboratory research. His research interests include investigating immunotherapy, gene therapy and targeted therapy for bladder cancer, and diagnostic modalities and new therapies for urologic malignancies. He has minor interests in investigating urinary tract infections, and medical device innovation.

He is an investigator in a number of grant-funded, clinical and basic science research projects. He was conferred a PhD (NUS) for his thesis on targeted therapy for bladder cancer. He also runs a number of clinical trials in bladder and prostate cancer. A/Prof Chiong has received more than 30 academic and fellowship awards, granted 2 patents for novel medical devices, authored or co-authored a number of papers in peer-reviewed journals, and have presented more than 120 abstracts at regional or international scientific meetings. He is also a reviewer for many leading international urology and cancer journals.

A/Prof Chiong is currently the President of the Singapore Urological Association, Vice Chairman of the Chapter of Urologists Surgeons (College of Surgeons), Academy of Medicine, Singapore, and the Chairman of the Exit Examinations Committee for Urology, Residency Advisory Committee / Joint Committee on Specialist Training (JCST), Ministry of Health, Singapore. He is also the National Representative for Singapore, in the Asia Pacific Society of Uro-Oncology, and a member of the American Urological Association and the American Society of Clinical Oncology. 

Research and Publications

  1. Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer. Lu S, Xu L, Kang ET, Mahendran R, Chiong E, Neoh KG. Eur J Pharm Sci. 2016 Jan 15;84:103-115.
  2. Mucoadhesive Polyacrylamide Nanogel as a Potential Hydrophobic Drug Carrier for Intravesical Bladder Cancer Therapy. Lu SJ, Neoh KG, Kang ET, Mahendran R, Chiong E. Eur J Pharm Sci. 2015 May 25;72:57-68.
  3. Functionalized Mesoporous Silica Nanoparticles with Mucoadhesive and Sustained Drug Release Properties for Potential Bladder Cancer Therapy. Zhang Q, Neoh KG, Xu LQ, Lu SJ, Kang ET, Mahendran R, Chiong E. Langmuir 2014 Jun 3;30(21):6151-61.
  4. Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Williams S, Chiong E (Co-1st author), Lojanapiwat B, Umbas R, Akaza H. Lancet Oncology 2013 Nov;14(12):e524-34.
  5. Guidelines on Management of Prostate Cancer. Sim HG, Lim KHC, Tay MH, Chong KT, Chiong E. Annals Academy of Medicine, Singapore 2013 Apr;42(4):190-9.
  6. Management of Kidney Cancer in Asia: Consensus Statement from the Asian Oncology Summit 2012. Chiong E, Tay MH, Tan MH, Kumar S, Sim HG, Teh BT, Umbas R, Chau NM. Lancet Oncology 2012 Nov;13(11):e482-91.
  7. Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells. Chiong E, Lee I, Dadbin A, Sabichi AL, Harris L, Urbauer D, McConkey D, Dickstein RJ, Cheng T, Grossman HB. Clin Cancer Res. 2011 May 1; 17(9):2863-73.
  8. NRAMP1 and hGPX1 Gene Polymorphism and Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer. Chiong E, Kesavan A, Mahendran R, Chan YH, Sng JH, Lim YK, Kamaraj R, Tan TM, Esuvaranathan K. Eur Urol. 2011;59(3):430-7.
  9. New Therapies for Non-muscle-invasive Bladder Cancer. Chiong E, Esuvaranathan K. World J Urol. 2010; 28(1):71-8.
  10. Role of cytoreductive nephrectomy in renal cell carcinoma. Chiong E, Wood CG, Margulis V. Future Oncol. 2009 Aug;5(6):859-69.